Company intelligence
Skye Bioscience Inc.
Unlocking new therapeutic pathways for metabolic health
Biotechnology Research
San Diego, US
11–50 employees
Founded 2011
1 public signals
About Skye Bioscience Inc.
Skye Bioscience (Nasdaq: SKYE) is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist (Wegovy®).
Verified activity
Signals from Skye Bioscience Inc.
1 published signal